Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic oral vinorelbine maintenance versus best supportive care in HER2-negative endocrine-resistant metastatic breast cancer
2016-002674-12Phase 2Terminated
- Sponsor
- Asociación Terapéutica Investigación Oncológica
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Metronomic oral vinorelbine maintenance with Best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Sep 2016; status: terminated.
02
Drugs
vinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002674-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002674-12.